Akihito Hagihara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akihito Hagihara has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Daisuke Onozuka
Center for Advanced Modalities and DDS (CAMaD), The University of Osaka, Osaka, Japan
30 shared publications - Takeru Abe
Center for Integrated Sciences and Humanities Fukushima Medical University Fukushima Japan
20 shared publications Manabu Hasegawa
General Affairs Division, Health Service Bureau, Ministry of Health, Labour and Welfare, 2-2 Kasumigaseki 1-chome, Chiyoda-ku, Tokyo 100-8916, Japan
13 shared publicationsTakashi Nagata
Department of Emergency and Critical Care Center, Kyushu University Hospital, Higashi-ku, Fukuoka 812-8582, Japan
13 shared publicationsKoichi Nobutomo
Department of Health Services Management and Policy , Kyushu University Graduate School of Medicine , Fukuoka , Japan
9 shared publicationsKimio Tarumi
Amagasaki City Health Center
7 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by Elsevier in Exploratory Research in Clinical and Social Pharmacy
- Vol. 23
Medication literacy scale for patients with chronic constipation
- 14 May 2026
- Published by Elsevier in Exploratory Research in Clinical and Social Pharmacy
- Vol. 23
Open AccessMedication literacy scale for patients with chronic constipation
- Open Access
Lifestyle Pathways Affecting Children’s Mental Health in Japan during the COVID-19 Pandemic
The recent prolonged COVID-19 pandemic has worsened the daily lives of preschoolers and elementary school children worldwide. Although these changes may have affected their mental health, the full picture still remains unknown. Since March 2020, Japan has intermittently experienced several COVID-19 waves. This survey was conducted between February and March 2022. In this study, we investigated the pathways by which specific lifestyle factors (such as exercise, sleep, diet, and life skills) affect physical/psychosocial health (PPH) in 1183 preschoolers (3–5 years old) and 3156 elementary school children (6–11 years old) in Toyama Prefecture, Japan. These pathways were examined using a path analysis. Consequently, “life skills” was found to be the factor most strongly associated with PPH in both preschoolers and elementary school children (p < 0.001). Furthermore, it was associated with the physical activity score and with PPH via physical activity. Moreover, both boys’ and girls’ mental health declined with age among elementary school children (p < 0.001). The results of the current study may be helpful for early interventions (around the start of elementary school) at home and at school to improve children’s mental health during the COVID-19 pandemic.
Open AccessLifestyle Pathways Affecting Children’s Mental Health in Japan during the COVID-19 Pandemic
The recent prolonged COVID-19 pandemic has worsened the daily lives of preschoolers and elementary school children worldwide. Although these changes may have affected their mental health, the full picture still remains unknown. Since March 2020, Japan has intermittently experienced several COVID-19 waves. This survey was conducted between February and March 2022. In this study, we investigated the pathways by which specific lifestyle factors (such as exercise, sleep, diet, and life skills) affect physical/psychosocial health (PPH) in 1183 preschoolers (3–5 years old) and 3156 elementary school children (6–11 years old) in Toyama Prefecture, Japan. These pathways were examined using a path analysis. Consequently, “life skills” was found to be the factor most strongly associated with PPH in both preschoolers and elementary school children (p < 0.001). Furthermore, it was associated with the physical activity score and with PPH via physical activity. Moreover, both boys’ and girls’ mental health declined with age among elementary school children (p < 0.001). The results of the current study may be helpful for early interventions (around the start of elementary school) at home and at school to improve children’s mental health during the COVID-19 pandemic.
- Open Access
- 1 March 2021
- Published by Elsevier in Journal of Cancer Policy
- Vol. 27, 100261
Employing multiple-attribute utility technology to evaluate publicity activities for cancer information and counseling programs in Japan
- 1 March 2021
- Published by Elsevier in Journal of Cancer Policy
- Vol. 27, 100261
Open AccessEmploying multiple-attribute utility technology to evaluate publicity activities for cancer information and counseling programs in Japan
- Open Access
- 9 April 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4) , e0230953
Effect of treatment modality and cerebral vasospasm agent on patient outcomes after aneurysmal subarachnoid hemorrhage in the elderly aged 75 years and older
We sought to examine whether the effect of treatment modality and drugs for cerebral vasospasm on clinical outcomes differs between elderly and non-elderly subarachnoid hemorrhage (SAH) patients in Japan. We analyzed the J-ASPECT Study Diagnosis Procedure Combination database (n = 17,343) that underwent clipping or coiling between 2010 and 2014 in 579 hospitals. We stratified patients into two groups according to their age (elderly [≥75 years old], n = 3,885; non-elderly, n = 13,458). We analyzed the effect of treatment modality and anti-vasospasm agents (fasudil hydrochloride, ozagrel sodium, cilostazol, statin, eicosapentaenoic acid [EPA], and edaravone) on in-hospital poor outcomes (mRS 3–6 at discharge) and mortality using multivariable analysis. The elderly patients were more likely to be female, have impaired levels of consciousness and comorbidity, and less likely to be treated with clipping and anti-vasospasm agents, except for ozagrel sodium and statin. In-hospital mortality and poor outcomes were higher in the elderly (15.8% vs. 8.5%, 71.7% vs. 36.5%). Coiling was associated with higher mortality (odds ratio 1.43, 95% confidence interval 1.2–1.7) despite a lower proportion of poor outcomes (0.84, 0.75–0.94) in the non-elderly, in contrast to no effect on clinical outcomes in the elderly. A comparable effect of anti-vasospasm agents on mortality was observed between non-elderly and elderly for fasudil hydrochloride (non-elderly: 0.20, 0.17–0.24), statin (0.63, 0.50–0.79), ozagrel sodium (0.72, 0.60–0.86), and cilostazol (0.63, 0.51–0.77). Poor outcomes were inversely associated with fasudil hydrochloride (0.59, 0.51–0.68), statin (0.84, 0.75–0.94), and EPA (0.83, 0.72–0.94) use in the non-elderly. No effect of these agents on poor outcomes was observed in the elderly. In contrast to the non-elderly, no effect of treatment modality on clinical outcomes were observed in the elderly. A comparable effect of anti-vasospasm agents was observed on mortality, but not on functional outcomes, between the non-elderly and elderly.
- 9 April 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4) , e0230953
Open AccessEffect of treatment modality and cerebral vasospasm agent on patient outcomes after aneurysmal subarachnoid hemorrhage in the elderly aged 75 years and older
We sought to examine whether the effect of treatment modality and drugs for cerebral vasospasm on clinical outcomes differs between elderly and non-elderly subarachnoid hemorrhage (SAH) patients in Japan. We analyzed the J-ASPECT Study Diagnosis Procedure Combination database (n = 17,343) that underwent clipping or coiling between 2010 and 2014 in 579 hospitals. We stratified patients into two groups according to their age (elderly [≥75 years old], n = 3,885; non-elderly, n = 13,458). We analyzed the effect of treatment modality and anti-vasospasm agents (fasudil hydrochloride, ozagrel sodium, cilostazol, statin, eicosapentaenoic acid [EPA], and edaravone) on in-hospital poor outcomes (mRS 3–6 at discharge) and mortality using multivariable analysis. The elderly patients were more likely to be female, have impaired levels of consciousness and comorbidity, and less likely to be treated with clipping and anti-vasospasm agents, except for ozagrel sodium and statin. In-hospital mortality and poor outcomes were higher in the elderly (15.8% vs. 8.5%, 71.7% vs. 36.5%). Coiling was associated with higher mortality (odds ratio 1.43, 95% confidence interval 1.2–1.7) despite a lower proportion of poor outcomes (0.84, 0.75–0.94) in the non-elderly, in contrast to no effect on clinical outcomes in the elderly. A comparable effect of anti-vasospasm agents on mortality was observed between non-elderly and elderly for fasudil hydrochloride (non-elderly: 0.20, 0.17–0.24), statin (0.63, 0.50–0.79), ozagrel sodium (0.72, 0.60–0.86), and cilostazol (0.63, 0.51–0.77). Poor outcomes were inversely associated with fasudil hydrochloride (0.59, 0.51–0.68), statin (0.84, 0.75–0.94), and EPA (0.83, 0.72–0.94) use in the non-elderly. No effect of these agents on poor outcomes was observed in the elderly. In contrast to the non-elderly, no effect of treatment modality on clinical outcomes were observed in the elderly. A comparable effect of anti-vasospasm agents was observed on mortality, but not on functional outcomes, between the non-elderly and elderly.
- 9 January 2019
- Published by Wiley in The American Journal on Addictions
- Vol. 28 (2) , 63-70
The association of tobacco use with prescription of muscle relaxants, benzodiazepines, and opioid analgesics for non‐cancer pain
Background and Objectives: Tobacco use and co‐prescription of sedative hypnotics are risk factors for misuse of prescribed opioids among patients with non‐cancer pain. However, the association between tobacco use and these co‐prescriptions has not been clarified. We aimed to assess differences in the prescription and co‐prescription rates of opioid analgesics with muscle relaxants and/or benzodiazepines between tobacco users and non‐users.Methods: Visit data were obtained from the 2006 to 2009 National Ambulatory Medical Care Survey, an annual cross‐sectional survey of visits to office‐based physicians in outpatient settings in the United States. Our sample patients were aged ≥18 years and diagnosed with non‐cancer back and neck pain. The χ2 test and multiple logistic regression analysis were used to assess bivariate and multivariate associations between prescription or co‐prescription rates and tobacco use status.Results: We analyzed a total of 114,199,536 weighted visits (unweighted number: 3,521). Significant odds ratios (ORs) of tobacco users (vs non‐users) for medical prescriptions were as follows: opioid analgesics, OR 2.14, 95% confidence interval (CI) 1.64–2.80; muscle relaxants and opioid analgesics, OR 2.57, 95%CI 1.76–3.74; benzodiazepines and opioid analgesics, OR 3.66, 95%CI 2.11–6.35, and muscle relaxants, benzodiazepines, and opioid analgesics, OR 7.02, 95%CI 2.98–16.57.Conclusions and Scientific Significance: Tobacco users were more likely to receive prescriptions for opioid analgesics with muscle relaxants and/or benzodiazepines than non‐users. Healthcare professionals need to limit co‐prescription of opioid analgesics with muscle relaxants and/or benzodiazepines among tobacco users and provide a comprehensive approach to pain management. (Am J Addict 2019;XX:1–8)
- 9 January 2019
- Published by Wiley in The American Journal on Addictions
- Vol. 28 (2) , 63-70
The association of tobacco use with prescription of muscle relaxants, benzodiazepines, and opioid analgesics for non‐cancer pain
Background and Objectives: Tobacco use and co‐prescription of sedative hypnotics are risk factors for misuse of prescribed opioids among patients with non‐cancer pain. However, the association between tobacco use and these co‐prescriptions has not been clarified. We aimed to assess differences in the prescription and co‐prescription rates of opioid analgesics with muscle relaxants and/or benzodiazepines between tobacco users and non‐users.Methods: Visit data were obtained from the 2006 to 2009 National Ambulatory Medical Care Survey, an annual cross‐sectional survey of visits to office‐based physicians in outpatient settings in the United States. Our sample patients were aged ≥18 years and diagnosed with non‐cancer back and neck pain. The χ2 test and multiple logistic regression analysis were used to assess bivariate and multivariate associations between prescription or co‐prescription rates and tobacco use status.Results: We analyzed a total of 114,199,536 weighted visits (unweighted number: 3,521). Significant odds ratios (ORs) of tobacco users (vs non‐users) for medical prescriptions were as follows: opioid analgesics, OR 2.14, 95% confidence interval (CI) 1.64–2.80; muscle relaxants and opioid analgesics, OR 2.57, 95%CI 1.76–3.74; benzodiazepines and opioid analgesics, OR 3.66, 95%CI 2.11–6.35, and muscle relaxants, benzodiazepines, and opioid analgesics, OR 7.02, 95%CI 2.98–16.57.Conclusions and Scientific Significance: Tobacco users were more likely to receive prescriptions for opioid analgesics with muscle relaxants and/or benzodiazepines than non‐users. Healthcare professionals need to limit co‐prescription of opioid analgesics with muscle relaxants and/or benzodiazepines among tobacco users and provide a comprehensive approach to pain management. (Am J Addict 2019;XX:1–8)
- 19 November 2018
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 30 (5) , 466-470
Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis
Background: A novel topical phosphodiesterase-4 inhibitor E6005 shows potential as effective treatment options for atopic dermatitis (AD); however, systemic exposure may cause potentially undesirable adverse reactions. In this study, we evaluated the relationship between the systemic exposure of E6005 and clinical parameters including skin condition and the incidence of AEs in patients with AD. Methods: The association analysis used the clinical data obtained in a previously conducted clinical study with topical E6005 in adult patients with AD. To estimate associations with drug exposure, generalized estimating equation logistic regression models were used, along with clinical data and plasma concentrations of M11, major metabolite of E6005 (as an indicator for E6005 exposure). Results: The metabolite M11 was detected in 62 of 221 plasma samples from 72 subjects. From association analysis, SCORAD-A obtained prior to E6005 treatment was identified as the clinical parameter influenced to M11 detection with statistical significance (p = 0.003). M11 detection was not clearly associated with the incidence of adverse events occurred. Conclusion: Exposure to topical E6005 is associated with the eczema-associated area, however, that is not distinctly associated with its adverse drug reactions occurred after drug applications possibly due to E6005’s characteristics of tissue distribution.
- 19 November 2018
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 30 (5) , 466-470
Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis
Background: A novel topical phosphodiesterase-4 inhibitor E6005 shows potential as effective treatment options for atopic dermatitis (AD); however, systemic exposure may cause potentially undesirable adverse reactions. In this study, we evaluated the relationship between the systemic exposure of E6005 and clinical parameters including skin condition and the incidence of AEs in patients with AD. Methods: The association analysis used the clinical data obtained in a previously conducted clinical study with topical E6005 in adult patients with AD. To estimate associations with drug exposure, generalized estimating equation logistic regression models were used, along with clinical data and plasma concentrations of M11, major metabolite of E6005 (as an indicator for E6005 exposure). Results: The metabolite M11 was detected in 62 of 221 plasma samples from 72 subjects. From association analysis, SCORAD-A obtained prior to E6005 treatment was identified as the clinical parameter influenced to M11 detection with statistical significance (p = 0.003). M11 detection was not clearly associated with the incidence of adverse events occurred. Conclusion: Exposure to topical E6005 is associated with the eczema-associated area, however, that is not distinctly associated with its adverse drug reactions occurred after drug applications possibly due to E6005’s characteristics of tissue distribution.
- 1 October 2018
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 118, 36-43
Impact of electronic medical records (EMRs) on hospital productivity in Japan
- 1 October 2018
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 118, 36-43
Impact of electronic medical records (EMRs) on hospital productivity in Japan
- 1 August 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 265, 240-245
Dispatcher-assisted bystander cardiopulmonary resuscitation and survival in out-of-hospital cardiac arrest
- 1 August 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 265, 240-245
Dispatcher-assisted bystander cardiopulmonary resuscitation and survival in out-of-hospital cardiac arrest
- Open Access
- 17 July 2018
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (14) , e009163
Grand Sumo Tournaments and Out‐of‐Hospital Cardiac Arrests in Tokyo
Background Sumo wrestling is a demanding sport. Although watching sumo wrestling may have cardiovascular effects, no studies of this relationship have been performed. Thus, we aimed to evaluate the association between sumo wrestling tournaments and the rate of out‐of‐hospital cardiac arrests. Methods and Results We counted the daily number of patients aged 18 to 110 years who had an out‐of‐hospital cardiac arrest of presumed‐cardiac origin in the Tokyo metropolis between 2005 and 2014. A Poisson regression was used to model out‐of‐hospital cardiac arrests of presumed‐cardiac origin per day. Exposure days were the days on which a sumo tournament was held and broadcast, whereas control days were all other days. Events that occurred on exposure days were compared with those that occurred on control days. Risk ratios for out‐of‐hospital cardiac arrests on Grand Sumo tournaments days compared with control days were estimated. In total, 71 882 out‐of‐hospital cardiac arrests met the inclusion criteria. We recorded a 9% increase in the occurrence of out‐of‐hospital cardiac arrests on the day of a sumo tournament compared with control days. In patients aged 75 to 110 years, we found a 13% increase in the occurrence of out‐of‐hospital cardiac arrests on the day of a sumo tournament compared with control days. Conclusions We found a significant increase in the occurrence of out‐of‐hospital cardiac arrests on the days of sumo tournaments compared with control days in the Tokyo metropolis between 2005 and 2014. Further studies are needed to verify these initial findings on sumo tournaments and cardiovascular events.
- 17 July 2018
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (14) , e009163
Open AccessGrand Sumo Tournaments and Out‐of‐Hospital Cardiac Arrests in Tokyo
Background Sumo wrestling is a demanding sport. Although watching sumo wrestling may have cardiovascular effects, no studies of this relationship have been performed. Thus, we aimed to evaluate the association between sumo wrestling tournaments and the rate of out‐of‐hospital cardiac arrests. Methods and Results We counted the daily number of patients aged 18 to 110 years who had an out‐of‐hospital cardiac arrest of presumed‐cardiac origin in the Tokyo metropolis between 2005 and 2014. A Poisson regression was used to model out‐of‐hospital cardiac arrests of presumed‐cardiac origin per day. Exposure days were the days on which a sumo tournament was held and broadcast, whereas control days were all other days. Events that occurred on exposure days were compared with those that occurred on control days. Risk ratios for out‐of‐hospital cardiac arrests on Grand Sumo tournaments days compared with control days were estimated. In total, 71 882 out‐of‐hospital cardiac arrests met the inclusion criteria. We recorded a 9% increase in the occurrence of out‐of‐hospital cardiac arrests on the day of a sumo tournament compared with control days. In patients aged 75 to 110 years, we found a 13% increase in the occurrence of out‐of‐hospital cardiac arrests on the day of a sumo tournament compared with control days. Conclusions We found a significant increase in the occurrence of out‐of‐hospital cardiac arrests on the days of sumo tournaments compared with control days in the Tokyo metropolis between 2005 and 2014. Further studies are needed to verify these initial findings on sumo tournaments and cardiovascular events.
- 23 April 2018
- Published by Springer Nature in International Archives of Occupational and Environmental Health
- Vol. 91 (5) , 613-622
The relationship between fine particulate matter (PM2.5) and schizophrenia severity
Although particulate matter (PM) is reported to affect the rate of emergency admissions for schizophrenia, no study has examined the relationship between particulate matter less than 2.5 μm in diameter (PM2.5) and the severity of schizophrenia.
- 23 April 2018
- Published by Springer Nature in International Archives of Occupational and Environmental Health
- Vol. 91 (5) , 613-622
The relationship between fine particulate matter (PM2.5) and schizophrenia severity
Although particulate matter (PM) is reported to affect the rate of emergency admissions for schizophrenia, no study has examined the relationship between particulate matter less than 2.5 μm in diameter (PM2.5) and the severity of schizophrenia.